Gilead’s Breakthrough CAR-T Becomes First to Get FDA Approval for Indolent Follicular Lymphoma
On March 5th, Kite Pharma, a Gilead Company, announced that Yescarta, a chimeric antigen receptor (CAR) T-cell therapy, has been approved for the treatment of relapsed or refractory follicular lymphoma …
Read More